John Sarantopoulos

5.3k citations
144 papers · 3.2k · 1 hit paper · h-index 30

Impact in

  • Oncology top 2%
    • Cancer Immunotherapy and Biomarkers
    • CAR-T cell therapy research
    • Peptidase Inhibition and Analysis

Papers in

    • Cancer Treatment and Pharmacology 29
    • Colorectal Cancer Treatments and Studies 11
    • Pancreatic and Hepatic Oncology Research 11

John Sarantopoulos

141 papers receiving 3.2k citations

John Sarantopoulos's Hit Papers

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors 2021 · 271 citations
2710+1+3Years since publication50100150200250

Peers

John Sarantopoulos
Comparison fields: 5 of 109
  • Oncology 1.1k
  • Cancer Research 316
  • Molecular Biology 1.4k
  • Immunology 419
  • Genetics 201
Replace Wijnand Helfrich with:
Wijnand Helfrich Netherlands
Maarten L. Janmaat Netherlands
Kyle D. Holen United States
Dominic Fan United States
Ling Geng United States
Ben Markman Australia
Michael Hölzel Germany
Terence O’Reilly Switzerland
Dmitri Wiederschain United States
Olivier Dormond Switzerland
John Sarantopoulos relative to Wijnand Helfrich Netherlands Wijnand Helfrich's profile →
Citations per field
00.5×1.5×2.3×
Wijnand Helfrich · 1×
Citations per year

Countries citing papers authored by John Sarantopoulos

Since Specialization
Citations

This map shows the geographic impact of John Sarantopoulos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Sarantopoulos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Sarantopoulos more than expected).

Fields of papers citing papers by John Sarantopoulos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Sarantopoulos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Sarantopoulos. The network helps show where John Sarantopoulos may publish in the future.

Co-authors

The 25 scholars most cited alongside John Sarantopoulos, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John Sarantopoulos Line = papers co-authored together John Sarantopoulos links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 144 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors
Hit paper breakdown →
2021271
2 2014245
3 2009238
4 2014187
5 2013146
6 2011140
7 2015140
8 201086
9 201086
10 201774
11 201972
12 201270
13 201669
14 201861
15 201260
16 202057
17 201149
18 201748
19 201947
20 200840

About John Sarantopoulos

John Sarantopoulos is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 144 papers that have together received 3.2k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (29 papers), Lung Cancer Treatments and Mutations (17 papers), Cancer, Hypoxia, and Metabolism (16 papers), Radiopharmaceutical Chemistry and Applications (14 papers), Colorectal Cancer Treatments and Studies (11 papers), Pancreatic and Hepatic Oncology Research (11 papers), Microtubule and mitosis dynamics (9 papers) and Cancer Genomics and Diagnostics (9 papers). The work is most often cited by research in Oncology (1.1k citations), Cancer Research (316 citations), Molecular Biology (1.4k citations), Immunology (419 citations) and Genetics (201 citations). John Sarantopoulos has collaborated with scholars based in United States, Japan and Switzerland. Frequent co-authors include Devalingam Mahalingam, Alain C. Mita, Monica Mita, Anthony W. Tolcher, Kamalesh K. Sankhala, Tyler J. Curiel, Francis J. Giles, Jordi Rodón, Chia‐Chi Lin and Jennifer S. Carew. Their work appears in journals such as Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, Molecular Cancer Therapeutics, Clinical Cancer Research and Investigational New Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact